ReproNovo Named to 2026 Fierce 15 Biotech List
The reproductive health startup joined the annual list of companies chosen for their clinical progress.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you trust that current fertility and women's health research is meeting your medical needs?
Fierce Biotech has selected Lausanne-based ReproNovo as one of 15 firms for its 2026 Fierce 15 list. The annual selection highlights private biotechnology companies based on their technology and clinical development approach.
Why it matters
ReproNovo earned the recognition for its focus on addressing unmet needs in male infertility and women's health. The selection highlights the company's progress in advancing therapeutic candidates through global clinical trials.
The list recognizes firms selected from hundreds of global companies based on venture backing, partnerships, and market position. ReproNovo manages development programs for RPN-001, targeting male infertility, and RPN-002, for female fertility and adenomyosis.
The players
ReproNovo
A Swiss-based biotechnology company developing therapeutic candidates for male infertility and adenomyosis.
Fierce Biotech
An industry publication that has published the Fierce 15 list annually for 24 years to highlight notable private life science firms.
The details
ReproNovo utilizes a multi-site development strategy with teams in Lausanne, Copenhagen, and Barcelona to manage global clinical trials. The company's pipeline includes RPN-001, a candidate for male infertility, and RPN-002, which is being studied for adenomyosis—a condition where the lining of the uterus grows into the muscular wall—and other female fertility indications. Clinical evaluations for these programs are currently active across the U.S., Europe, and China.
Timeline
October 5, 2026: Fierce Biotech announced the 2026 Fierce 15 list.
The Tech Race
The selection continues the 24-year precedent of the Fierce 15 list in identifying private startups with the potential to scale their therapeutic pipelines. By focusing on male infertility and adenomyosis, ReproNovo targets niche areas of reproductive medicine that remain heavily underserved by current therapies.
ReproNovo's current clinical trials for RPN-001 and RPN-002 remain in active development across the U.S., Europe, and China. Patients and clinicians should monitor future trial disclosures for specific data regarding the efficacy of these infertility treatments.
The takeaway
This recognition confirms that ReproNovo's pipeline is attracting significant industry attention. Interested observers should monitor the company's future clinical trial readouts to assess the potential impact of their fertility candidates.
Further reading
For more on the current state of reproductive medicine research, visit the Biotech section.
More information
Learn more about the company's research pipeline on the ReproNovo company website.
Live Poll
Do you trust that current fertility and women's health research is meeting your medical needs?
